ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 2046

Implementation of an Automated Transition Readiness Assessment in a Pediatric Rheumatology Clinic

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 1905

Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic

(1895–1912) Measures & Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1906

Implementation Practices for the 2022 American College of Rheumatology Guidelines for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis

(1895–1912) Measures & Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1925

Importance of the Patient Pain Experience in Disease Activity Assessment in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Study

(1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

9:00AM-11:00AM: Abstract Number: L06

Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)

Late-Breaking Abstract Poster

9:00AM-11:00AM: Abstract Number: 2006

Improvement of Care: Osteoporosis Screening in a Resident-led Primary Care Clinic

(1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1856

Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project

(1840–1861) Health Services Research Poster III

9:00AM-11:00AM: Abstract Number: 1902

Improving the Sharing of Information from Reviews of Measurement Properties: The OMERACT Summary of Measurement Properties (SOMP) Table

(1895–1912) Measures & Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1708

In Cis SOCS1 Variants Illustrate the Precise Regulation of Interferon Signaling Needed to Prevent Autoimmunity

(1705–1712) Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1897

In Pursuit of Excellence: Improving Systemic Sclerosis Quality of Care

(1895–1912) Measures & Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2012

Incidence of Hyperparathyroidism in Patients with Osteoporosis Treated with Zoledronic Acid or Denosumab

(1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2348

Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years

(2326–2351) SLE – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 2363

Increase in Macrophage Infiltration in Scleroderma Esophageal Mucosa Is Associated with Motility and Mucosal Complications

(2352–2369) Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science

9:00AM-11:00AM: Abstract Number: 2206

Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis

(2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

9:00AM-11:00AM: Abstract Number: 2178

Increased Risk of Dementia in Patients with Primary Sjogren’s Syndrome: A Nationwide Population-based Cohort Study

(2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].